Benitec Biopharma Inc
BNTC12.960USD
+0.610+4.94%
Close 12/23, 16:00（ET）Quotes delayed by 15 min
340.21MMarket Cap
LossP/E TTM
More Details of Benitec Biopharma Inc Company
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Benitec Biopharma Inc Info
Ticker SymbolBNTC
Company nameBenitec Biopharma Inc
IPO dateJul 11, 2012
CEOBanks (Jerel A)
Number of employees19
Security typeOrdinary Share
Fiscal year-endJul 11
Address3940 Trust Way
CityHAYWARD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94545
Phone15107800819
Websitehttps://benitec.com/
Ticker SymbolBNTC
IPO dateJul 11, 2012
CEOBanks (Jerel A)
Company Executives of Benitec Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Megan Joan Boston
Ms. Megan Joan Boston
Chief Financial Officer, Executive Director, Secretary
Chief Financial Officer, Executive Director, Secretary
25.93K
--
Ms. Sophie Mukadam
Ms. Sophie Mukadam
Chief Operating Officer
Chief Operating Officer
6.02K
--
Mr. Peter Damian Francis
Mr. Peter Damian Francis
Independent Director
Independent Director
297.00
--
Buchi (J Kevin)
Buchi (J Kevin)
Independent Director
Independent Director
--
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Independent Director
Independent Director
--
--
Dr. Sharon Mates, Ph.D.
Dr. Sharon Mates, Ph.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Managing Director
Managing Director
--
--
Dr. Jerel A. Banks, M.D., Ph.D.
Dr. Jerel A. Banks, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Edward F. Smith
Mr. Edward F. Smith
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Megan Joan Boston
Ms. Megan Joan Boston
Chief Financial Officer, Executive Director, Secretary
Chief Financial Officer, Executive Director, Secretary
25.93K
--
Ms. Sophie Mukadam
Ms. Sophie Mukadam
Chief Operating Officer
Chief Operating Officer
6.02K
--
Mr. Peter Damian Francis
Mr. Peter Damian Francis
Independent Director
Independent Director
297.00
--
Buchi (J Kevin)
Buchi (J Kevin)
Independent Director
Independent Director
--
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Independent Director
Independent Director
--
--
Dr. Sharon Mates, Ph.D.
Dr. Sharon Mates, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2023
FY2022
FY2021
FY2019
By BusinessUSD
Name
Revenue
Proportion
Licensing revenue
75.00K
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Licensing revenue
75.00K
0.00%
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Suvretta Capital Management, LLC
33.54%
Janus Henderson Investors
8.60%
Franklin Advisers, Inc.
7.65%
Adage Capital Management, L.P.
5.83%
RA Capital Management, LP
5.46%
Other
38.92%
Shareholders
Shareholders
Proportion
Suvretta Capital Management, LLC
33.54%
Janus Henderson Investors
8.60%
Franklin Advisers, Inc.
7.65%
Adage Capital Management, L.P.
5.83%
RA Capital Management, LP
5.46%
Other
38.92%
Shareholder Types
Shareholders
Proportion
Hedge Fund
44.05%
Investment Advisor/Hedge Fund
19.90%
Investment Advisor
11.78%
Venture Capital
5.46%
Corporation
2.20%
Research Firm
0.61%
Individual Investor
0.53%
Bank and Trust
0.04%
Insurance Company
0.02%
Other
15.40%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
104
27.71M
70.75%
+3.33M
2025Q3
104
24.38M
91.26%
+455.37K
2025Q2
100
23.88M
84.92%
+1.54M
2025Q1
61
22.35M
78.36%
+2.34M
2024Q4
55
20.11M
70.30%
+3.66M
2024Q3
51
14.59M
41.10%
+7.39M
2024Q2
50
7.24M
58.15%
+2.08M
2024Q1
47
1.32M
57.31%
-243.94K
2023Q4
48
1.24M
60.74%
-70.36K
2023Q3
50
1.31M
59.46%
+42.18K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Suvretta Capital Management, LLC
9.88M
37.62%
--
--
Jun 30, 2025
Janus Henderson Investors
2.90M
11.06%
-16.16K
-0.55%
Jun 30, 2025
Franklin Advisers, Inc.
2.70M
10.29%
-159.28K
-5.57%
Jun 30, 2025
Adage Capital Management, L.P.
1.97M
7.51%
--
--
Jun 30, 2025
HBM Partners AG
1.04M
3.97%
+200.27K
+23.80%
Dec 31, 2024
The Vanguard Group, Inc.
969.17K
3.69%
+642.13K
+196.35%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
661.64K
2.52%
+477.75K
+259.80%
Jun 30, 2025
Nantahala Capital Management, LLC
838.10K
3.19%
--
--
Jun 30, 2025
Nemean Asset Management, LLC
746.32K
2.84%
+648.12K
+659.98%
Apr 22, 2024
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Health Care ETF
1.08%
iShares Neuroscience and Healthcare ETF
0.53%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
View more
Simplify Health Care ETF
Proportion1.08%
iShares Neuroscience and Healthcare ETF
Proportion0.53%
iShares Micro-Cap ETF
Proportion0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 25, 2023
Merger
17→1
Jul 25, 2023
Merger
17→1
Jul 25, 2023
Merger
17→1
Jul 25, 2023
Merger
17→1
Date
Type
Ratio
Jul 25, 2023
Merger
17→1
Jul 25, 2023
Merger
17→1
Jul 25, 2023
Merger
17→1
Jul 25, 2023
Merger
17→1
FAQs
Who are the top five shareholders of Benitec Biopharma Inc?
The top five shareholders of Benitec Biopharma Inc are:
Suvretta Capital Management, LLC holds 9.88M shares, accounting for 37.62% of the total shares.
Janus Henderson Investors holds 2.90M shares, accounting for 11.06% of the total shares.
Franklin Advisers, Inc. holds 2.70M shares, accounting for 10.29% of the total shares.
Adage Capital Management, L.P. holds 1.97M shares, accounting for 7.51% of the total shares.
HBM Partners AG holds 1.04M shares, accounting for 3.97% of the total shares.
Suvretta Capital Management, LLC holds 9.88M shares, accounting for 37.62% of the total shares.
Janus Henderson Investors holds 2.90M shares, accounting for 11.06% of the total shares.
Franklin Advisers, Inc. holds 2.70M shares, accounting for 10.29% of the total shares.
Adage Capital Management, L.P. holds 1.97M shares, accounting for 7.51% of the total shares.
HBM Partners AG holds 1.04M shares, accounting for 3.97% of the total shares.
What are the top three shareholder types of Benitec Biopharma Inc?
The top three shareholder types of Benitec Biopharma Inc are:
Suvretta Capital Management, LLC
Janus Henderson Investors
Franklin Advisers, Inc.
Suvretta Capital Management, LLC
Janus Henderson Investors
Franklin Advisers, Inc.
How many institutions hold shares of Benitec Biopharma Inc (BNTC)?
As of 2025Q4, 104 institutions hold shares of Benitec Biopharma Inc, with a combined market value of approximately 27.71M, accounting for 70.75% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -20.52%.
What is the biggest source of revenue for Benitec Biopharma Inc?
In FY2023, the Licensing revenue business generated the highest revenue for Benitec Biopharma Inc, amounting to 75.00K and accounting for --% of total revenue.
